Hipersensibilidad a Betalactámicos. Dra Yurlany Gutiérrez (20 de septiembre 2018)

De


Hipersensibilidad a Betalactámicos.  Dra Yurlany Gutiérrez (20 de septiembre 2018)

Comentarios

  1. Ricardo Cardona Villa21 de septiembre de 2018, 9:39

    Artículo recomendado:

    Cross-reactivity in b-Lactam Allergy
    Robert J. Zagursky, PhD, and Michael E. Pichichero, MD Rochester, NY

    b-Lactam drugs (penicillins, amoxicillin, and cephalosporins)
    account for 42.6% of all severe drug-induced anaphylaxis. In this
    review, we focus on clinically significant immunologic crossreactivity
    in patients with confirmed penicillin allergy to
    cephalosporins, and the structural involvement of the R1 and R2
    chemical side chains of the cephalosporins causing IgE-mediated
    cross-reactivity with penicillin and other cephalosporins. Skin
    tests predict IgE-mediated reactions and showed cross-reactivity
    between penicillins and early generation cephalosporins that
    shared side chains, but confirmatory challenge data are lacking.
    Later-generation cephalosporins, which have distinct side chains,
    do not have any skin test cross-reactivity with penicillin/
    amoxicillin. There is debate as to the involvement of R2 side
    chains as the antigenic determinants that cause IgE-mediated
    hypersensitivity with various cephalosporins. Avoidance of
    cephalosporins, when they are the drug of choice in a penicillinallergic individual, results in significant morbidity that outweighs the low risk of anaphylaxis. We conclude that there is ample evidence to allow the safe use of cephalosporins in patients with isolated confirmed penicillin or amoxicillinallergy.

    Texto completo:
    http://dx.doi.org/10.1016/j.jaip.2017.08.027

    ResponderEliminar

Publicar un comentario

Entradas populares de este blog

ICON: Diagnosis and management of allergic conjunctivitis. Miércoles 25 de marzo

De
ICON: Diagnosis and management of allergic conjunctivitis. Authors: Bielory L1, Delgado L2, Katelaris CH3, Leonardi A4, Rosario N5, Vichyanoud P6. Author information Abstract Ocular allergy (OA), interchangeably known as allergic conjunctivitis, is a common immunological hypersensitivity disorder affecting up to 40% of the population. Ocular allergy has been increasing in frequency, with symptoms of itching, redness, and swelling that significantly impacts an individual's quality of life (QOL). Ocular allergy is an often underdiagnosed and undertreated health problem, because only 10% of patients with OA symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary nonpharmacological remedies. The clinical course, duration, severity, and co-morbidities are varied and depend, in part, on the specific ocular tissues that are affected and on immunologic mechanism(s) involved, both local and systemic. It is frequently associat...
Leer más

Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19).

De
 Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19).  Fecha de actualización: viernes 20 de marzo 2020 Versión: 7 1. Introducción El 31 de diciembre de 2019 la Comisión Municipal de Salud y Sanidad de Wuhan (provincia de Hubei, China) informó sobre un agrupamiento de 27 casos de neumonía de etiología desconocida con inicio de síntomas el 8 de diciembre; los casos reportaban antecedente de exposición común a un mercado de mariscos, pescados y animales vivos en la ciudad de Wuhan. El 7 de enero de 2020, las autoridades chinas identificaron como agente causante del brote un nuevo tipo de virus de la familia Coronaviridae, que fue denominado “nuevo coronavirus”, SARS-COV-2 (1). Dado que los casos de coronavirus suelen causar síntomas respiratorios, la Organización Mundial de la Salud (OMS) ha emitido recomendaciones de protec...
Leer más

BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. Martes 14 de abril

De
BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study Authors: Jenneke Leentjens 1, Matthijs Kox 2, Robin Stokman 2, Jelle Gerretsen 2, Dimitri A Diavatopoulos 3, Reinout van Crevel 4, Guus F Rimmelzwaan 5, Peter Pickkers 2, Mihai G Netea 4 Abstract Background: Influenza-related morbidity and mortality remain high. Seasonal vaccination is the backbone of influenza management but does not always result in protective antibody titers. Nonspecific effects of BCG vaccination related to enhanced function of myeloid antigen-presenting cells have been reported. We hypothesized that BCG vaccination could also enhance immune responses to influenza vaccination. Methods: Healthy volunteers received either live attenuated BCG vaccine (n = 20) or placebo (n = 20) in a randomized fashion, followed by intramuscular injection of trivalent influenza vaccine 14 days later. Hemagglutination-inhibiting (H...
Leer más